PL2544657T3 - Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów - Google Patents
Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotówInfo
- Publication number
- PL2544657T3 PL2544657T3 PL11709793T PL11709793T PL2544657T3 PL 2544657 T3 PL2544657 T3 PL 2544657T3 PL 11709793 T PL11709793 T PL 11709793T PL 11709793 T PL11709793 T PL 11709793T PL 2544657 T3 PL2544657 T3 PL 2544657T3
- Authority
- PL
- Poland
- Prior art keywords
- amisulpride
- vomiting
- treating post
- operative nausea
- nausea
- Prior art date
Links
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 title 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 title 1
- 229960003036 amisulpride Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1004020.2A GB201004020D0 (en) | 2010-03-11 | 2010-03-11 | New therapeutic use |
| PCT/GB2011/050472 WO2011110854A2 (en) | 2010-03-11 | 2011-03-10 | The use of amisulpride as an anti-emetic |
| EP11709793.1A EP2544657B1 (en) | 2010-03-11 | 2011-03-10 | Use of amisulpride for treating post-operative nausea and vomiting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2544657T3 true PL2544657T3 (pl) | 2014-10-31 |
Family
ID=42136792
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11709793T PL2544657T3 (pl) | 2010-03-11 | 2011-03-10 | Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów |
| PL14173186T PL2796171T3 (pl) | 2010-03-11 | 2011-03-10 | Zastosowania amisulprydu w leczeniu nudności i wymiotów wywołanych przez opiat |
| PL12188047T PL2567690T3 (pl) | 2010-03-11 | 2011-03-10 | Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14173186T PL2796171T3 (pl) | 2010-03-11 | 2011-03-10 | Zastosowania amisulprydu w leczeniu nudności i wymiotów wywołanych przez opiat |
| PL12188047T PL2567690T3 (pl) | 2010-03-11 | 2011-03-10 | Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów |
Country Status (26)
| Country | Link |
|---|---|
| US (12) | US8686019B2 (enExample) |
| EP (3) | EP2796171B1 (enExample) |
| JP (2) | JP5886213B2 (enExample) |
| KR (1) | KR101738201B1 (enExample) |
| CN (1) | CN102892407B (enExample) |
| AU (1) | AU2011225898B2 (enExample) |
| BR (1) | BR112012022746B1 (enExample) |
| CA (1) | CA2792392C (enExample) |
| CY (3) | CY1115485T1 (enExample) |
| DK (3) | DK2567690T3 (enExample) |
| EA (1) | EA030335B1 (enExample) |
| ES (3) | ES2496099T3 (enExample) |
| GB (1) | GB201004020D0 (enExample) |
| HR (3) | HRP20140744T1 (enExample) |
| HU (1) | HUE037088T2 (enExample) |
| IL (1) | IL221746A (enExample) |
| LT (1) | LT2796171T (enExample) |
| MX (3) | MX370629B (enExample) |
| NO (1) | NO2796171T3 (enExample) |
| NZ (1) | NZ602279A (enExample) |
| PL (3) | PL2544657T3 (enExample) |
| PT (3) | PT2796171T (enExample) |
| RS (3) | RS53466B (enExample) |
| SI (3) | SI2796171T1 (enExample) |
| SM (3) | SMT201800188T1 (enExample) |
| WO (1) | WO2011110854A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201004020D0 (en) * | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| CN104435861A (zh) * | 2014-12-22 | 2015-03-25 | 济南伟传信息技术有限公司 | 一种治疗妊娠剧吐的茶 |
| GB201506116D0 (en) | 2015-04-10 | 2015-05-27 | Acacia Pharma Ltd | Kit and combination therapy for nausea and vomiting |
| EP3344962A4 (en) | 2015-09-02 | 2019-03-13 | California Institute of Technology | METHOD AND DEVICE FOR THE SPECTROSCOPIC DETECTION OF LOW CONCENTRATIONS OF SULFUR HYDROGEN GAS |
| GB201618425D0 (en) | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) * | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| AU2018378348B2 (en) | 2017-12-05 | 2024-09-19 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| JP7268026B2 (ja) | 2017-12-05 | 2023-05-02 | サノビオン ファーマシューティカルズ インク | 非ラセミ混合物およびその使用 |
| WO2020247603A1 (en) * | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| WO2020247627A1 (en) | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| WO2022008901A1 (en) | 2020-07-06 | 2022-01-13 | Acacia Pharma Ltd | Therapy of post-operative nausea and vomiting |
| EP4496797A1 (en) | 2022-03-21 | 2025-01-29 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| CN119255988A (zh) | 2022-04-14 | 2025-01-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| AU2023396387A1 (en) | 2022-12-15 | 2025-06-26 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| WO2024138048A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2026501285A (ja) | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| US20250019389A1 (en) | 2023-06-30 | 2025-01-16 | Gasherbrum Bio, Inc. | Heterocyclic agonists |
| AR133240A1 (es) | 2023-07-13 | 2025-09-10 | Aconcagua Bio Inc | Compuestos, composiciones y métodos |
| AR133241A1 (es) | 2023-07-13 | 2025-09-10 | Aconcagua Bio Inc | Compuestos, composiciones y métodos |
| WO2025045208A1 (en) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2415099A1 (fr) * | 1978-01-20 | 1979-08-17 | Ile De France | Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes |
| US6169094B1 (en) * | 1998-07-14 | 2001-01-02 | Sanofi-Synthelabo | Compositions of (S) (-)-amisulpride |
| DE10163421A1 (de) | 2001-12-21 | 2003-07-31 | Gruenenthal Gmbh | Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum |
| DE102005013726A1 (de) * | 2005-03-22 | 2006-09-28 | Grünenthal GmbH | Transdermale therapeutische Systeme mit verbesserter Verträglichkeit |
| GB0506800D0 (en) * | 2005-04-04 | 2005-05-11 | Merck Sharp & Dohme | New uses |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| KR101413613B1 (ko) | 2006-01-27 | 2014-07-10 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템 |
| EP1988883A1 (fr) * | 2006-02-17 | 2008-11-12 | Trimaran Limited | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
| US7825156B2 (en) * | 2007-02-02 | 2010-11-02 | Copharms | Method of treating bipolar depression with a benzamide derivative |
| CA2905541C (en) * | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| WO2009126931A2 (en) * | 2008-04-11 | 2009-10-15 | Xvasive, Inc. | Combination therapy for bipolar disorder |
| GB201004020D0 (en) | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
-
2010
- 2010-03-11 GB GBGB1004020.2A patent/GB201004020D0/en not_active Ceased
-
2011
- 2011-03-10 JP JP2012556586A patent/JP5886213B2/ja active Active
- 2011-03-10 DK DK12188047.0T patent/DK2567690T3/da active
- 2011-03-10 PL PL11709793T patent/PL2544657T3/pl unknown
- 2011-03-10 SI SI201131446T patent/SI2796171T1/en unknown
- 2011-03-10 MX MX2015003664A patent/MX370629B/es unknown
- 2011-03-10 EA EA201290833A patent/EA030335B1/ru unknown
- 2011-03-10 CN CN201180018552.XA patent/CN102892407B/zh not_active Ceased
- 2011-03-10 SM SM20180188T patent/SMT201800188T1/it unknown
- 2011-03-10 CA CA2792392A patent/CA2792392C/en active Active
- 2011-03-10 MX MX2012010411A patent/MX2012010411A/es active IP Right Grant
- 2011-03-10 BR BR112012022746-7A patent/BR112012022746B1/pt active IP Right Grant
- 2011-03-10 SI SI201130237T patent/SI2567690T1/sl unknown
- 2011-03-10 EP EP14173186.9A patent/EP2796171B1/en active Active
- 2011-03-10 RS RS20140410A patent/RS53466B/sr unknown
- 2011-03-10 DK DK14173186.9T patent/DK2796171T3/en active
- 2011-03-10 PL PL14173186T patent/PL2796171T3/pl unknown
- 2011-03-10 DK DK11709793.1T patent/DK2544657T3/da active
- 2011-03-10 ES ES12188047.0T patent/ES2496099T3/es active Active
- 2011-03-10 LT LTEP14173186.9T patent/LT2796171T/lt unknown
- 2011-03-10 WO PCT/GB2011/050472 patent/WO2011110854A2/en not_active Ceased
- 2011-03-10 KR KR1020127024111A patent/KR101738201B1/ko active Active
- 2011-03-10 RS RS20140411A patent/RS53467B/sr unknown
- 2011-03-10 PL PL12188047T patent/PL2567690T3/pl unknown
- 2011-03-10 RS RS20180349A patent/RS57032B1/sr unknown
- 2011-03-10 MX MX2019015396A patent/MX388787B/es unknown
- 2011-03-10 EP EP11709793.1A patent/EP2544657B1/en active Active
- 2011-03-10 ES ES14173186.9T patent/ES2665418T3/es active Active
- 2011-03-10 HR HRP20140744AT patent/HRP20140744T1/hr unknown
- 2011-03-10 NO NO14173186A patent/NO2796171T3/no unknown
- 2011-03-10 EP EP12188047.0A patent/EP2567690B1/en active Active
- 2011-03-10 ES ES11709793.1T patent/ES2496092T3/es active Active
- 2011-03-10 PT PT141731869T patent/PT2796171T/pt unknown
- 2011-03-10 NZ NZ602279A patent/NZ602279A/en unknown
- 2011-03-10 SI SI201130236T patent/SI2544657T1/sl unknown
- 2011-03-10 HU HUE14173186A patent/HUE037088T2/hu unknown
- 2011-03-10 AU AU2011225898A patent/AU2011225898B2/en active Active
- 2011-03-10 PT PT117097931T patent/PT2544657E/pt unknown
- 2011-03-10 PT PT121880470T patent/PT2567690E/pt unknown
-
2012
- 2012-07-26 US US13/559,253 patent/US8686019B2/en active Active
- 2012-07-26 US US13/559,168 patent/US9084765B2/en active Active
- 2012-09-02 IL IL221746A patent/IL221746A/en active IP Right Grant
-
2014
- 2014-02-04 US US14/172,194 patent/US9119836B2/en active Active
- 2014-08-01 HR HRP20140745AT patent/HRP20140745T1/hr unknown
- 2014-08-14 CY CY20141100656T patent/CY1115485T1/el unknown
- 2014-08-14 CY CY20141100657T patent/CY1115487T1/el unknown
- 2014-09-10 SM SM201400126T patent/SMT201400126B/xx unknown
- 2014-09-10 SM SM201400127T patent/SMT201400127B/xx unknown
-
2015
- 2015-07-29 US US14/812,148 patent/US9545426B2/en active Active
- 2015-09-24 JP JP2015187057A patent/JP6279526B2/ja active Active
-
2016
- 2016-12-09 US US15/374,174 patent/US9889118B2/en active Active
-
2017
- 2017-10-23 US US15/790,481 patent/US10085970B2/en active Active
-
2018
- 2018-03-14 HR HRP20180436TT patent/HRP20180436T1/hr unknown
- 2018-04-18 CY CY20181100416T patent/CY1120170T1/el unknown
- 2018-08-20 US US16/105,268 patent/US10525033B2/en active Active
-
2019
- 2019-11-27 US US16/697,986 patent/US20200093792A1/en not_active Abandoned
-
2020
- 2020-09-08 US US17/013,987 patent/US20210228543A1/en not_active Abandoned
-
2022
- 2022-06-07 US US17/834,000 patent/US20220296570A1/en not_active Abandoned
-
2023
- 2023-01-11 US US18/095,612 patent/US12194022B2/en active Active
-
2024
- 2024-12-06 US US18/972,484 patent/US20250186394A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2544657E (pt) | Uso de amissulprida para tratar náusea e vómito pósoperatório | |
| EP2523630A4 (en) | SYSTEMS AND METHODS FOR BARIATRIC THERAPY | |
| EP2603250A4 (en) | Wound treatment and containment arrangement | |
| IL226331A0 (en) | Bromodomain inhibitors and their use | |
| ZA201305495B (en) | Compounds and their use as bace inhibitors | |
| EP2549963A4 (en) | Systems and methods for prostate treatment | |
| ZA201303605B (en) | Compounds and methods for treating pain | |
| ZA201208948B (en) | Modified beta-lactamases and methods and uses related thereto | |
| EP2574172A4 (en) | MATERIALS AND METHOD FOR TREATING INFLAMMATION | |
| ZA201300036B (en) | Banzamide derivatives and their use as hsp90 inhibitors | |
| SI2557084T1 (sl) | Kalcijev rosuvastatin polizdelek in postopek za njegovo pripravo | |
| ZA201208895B (en) | Bicyclic compound derivatives and their use as acc inhibitors | |
| ZA201209666B (en) | Salts and polymorhs of dexrabeprazole | |
| EP2566483A4 (en) | METHOD AND MEANS FOR IMPROVED WOUND HEALING | |
| EP2624854A4 (en) | MOESIN MODULATORS AND ITS USES | |
| EP2538951A4 (en) | Agents and mechanisms for treating hypercholesterolemia | |
| WO2012057895A9 (en) | Composition and method for treating wounds | |
| GB201016486D0 (en) | Compounds for the use in treatment of plants | |
| AU2010904485A0 (en) | Agents and Methods for Treating Hematologic Conditions | |
| AU2010901243A0 (en) | Security device and method of manufacture | |
| HK1187900A (en) | Inhibitors of pi3k-delta and methods of their use and manufacture | |
| HK1180935A (en) | Systems and methods for prostate treatment | |
| HK1184329A (en) | Oligo-benzamide compounds and their use | |
| HK1179175A (en) | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof | |
| GB201017098D0 (en) | Carbonic anhydrase inhibitors |